Navigation Links
UCLA Performs First 'Breathing Lung' Transplant In United States
Date:11/26/2012

LOS ANGELES, Nov. 26, 2012 /PRNewswire-USNewswire/ -- First there was the "heart in a box," a revolutionary experimental technology that allows donor hearts to be delivered to transplant recipients warm and beating rather than frozen in an ice cooler.  

Now that same technology is being used to deliver "breathing lungs." 

The lung transplant team at Ronald Reagan UCLA Medical successfully performed the nation's first "breathing lung" transplant in mid-November. The patient, a 57-year-old who suffered from pulmonary fibrosis -- a disease in which the air sacs of the lungs are gradually replaced by scar tissue -- received two new lungs and is recuperating from the seven-hour surgery.  

The groundbreaking transplant involved an experimental organ-preservation device known as the Organ Care System (OCS), which keeps donor lungs functioning and "breathing" in a near-physiologic state outside the body during transport. The current standard involves transporting donor lungs in a non-functioning, non-breathing state inside an icebox.  

With the OCS, the lungs are removed from a donor's body and are placed in a high-tech OCS box, where they are immediately revived to a warm, breathing state and perfused with oxygen and a special solution supplemented with packed red-blood cells. The device also features monitors that display how the lungs are functioning during transport. 

"Organs were never meant to be frozen on ice," said Dr. Abbas Ardehali, a professor of cardiothoracic surgery and director of the heart and lung transplantation program at Ronald Reagan UCLA Medical Center. "Lungs are very sensitive and can easily be damaged during the donation process. The cold storage method does not allow for reconditioning of the lungs before transplantation, but this promising 'breathing lung' technology enables us to potentially improve the function of the donor lungs before they are placed in the recipient."  

UCLA is currently leading the U.S. arm of the international, multicenter phase 2 clinical INSPIRE study of the OCS, developed by medical device company TransMedics; Ardehali is the principal investigator for UCLA. The purpose of the trial is to compare donor lungs transported using the OCS technology with the standard icebox method. The INSPIRE trial is also underway at lung transplant centers in Europe, Australia and Canada and will enroll a total of 264 randomized patients. 

According to Ardehali, in addition to potentially improving donor-lung function, the technology could help transplant teams better assess donor lungs, since the organs can be tested in the device, over a longer period of time. 

In addition, it could help expand the donor pool by allowing donor lungs to be safely transported across longer distances. 

"For patients with end-stage lung disease, lung transplantation can dramatically improve the patient's symptoms and offer relief from severe shortness of breath," said Dr. David Ross, professor of medicine and medical director of UCLA's lung and heart-lung transplantation program and UCLA's pulmonary arterial hypertension and thromboendarterectomy program. "The 'breathing lung' technology could potentially make the transplantation process even better and improve the outcomes for patients suffering from lung disease."   

The "breathing lung" device follows on the heels of TransMedics' "heart in a box" technology, which delivers donor hearts in a similar manner. The multi-center national study of the heart technology, also led by UCLA, is ongoing. 

Results of a preliminary OCS lung study conducted in Europe were published in the Oct. 10 edition of the journal Lancet. The findings showed good lung transplantation outcomes following preservation using the OCS system. Read the Lancet study at http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2812%2961344-0/abstract

UCLA's lung and heart-lung transplant program is the largest lung transplantation program on the West Coast and leads the nation in patient outcomes. The program pioneers novel technologies in lung preservation, recipient immune monitoring and immunosuppression and is responsible for significant advances in transplantation for extremely ill and high-risk transplant candidates.

For more information about UCLA's lung transplantation program and the INSPIRE trial, visit www.transplant.ucla.edu/lung

Headquartered outside Boston, Mass., TransMedics Inc. is a privately held medical device company founded in 1998 to address the vital, unmet need for better, more effective organ transplant technologies. For more information, visit www.transmedics.com.   

Ardehali has no financial ties to disclose.  

For more news, visit the UCLA Newsroom and follow us on Twitter.
Provided by Newswise, online resource for knowledge-based news at www.newswise.com

http://www.youtube.com/watch?feature=player_embedded&v=QCe8XZqlGNg
(Note to editors: B-roll footage and photos are available.)

Media Contacts:
Amy Albin, aalbin@mednet.ucla.edu
310-794-8672

This news release was issued on behalf of Newswise(TM). For more information, visit http://www.newswise.com.


'/>"/>
SOURCE University of California, Los Angeles (UCLA), Health Sciences
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Golden Seeds Invests In DxUpClose, Disruptive Technology That Performs An Antibiotic Sensitivity Test At The Patients Bedside In Less Than An Hour
2. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
3. Thoratec Schedules First Quarter Conference Call, Webcast
4. Watson to Host Conference Call and Webcast to Discuss First Quarter 2012 Earnings
5. CVS Caremark Corporation to Hold First Quarter 2012 Conference Call
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. Alexza to Announce 2012 First Quarter Financial Results on Thursday, May 10, 2012
8. 3SBio Inc. Schedules Unaudited First Quarter 2012 Results
9. Insmed to Host 2012 First Quarter Earnings Conference Call
10. Simcere Pharmaceutical Group to Announce First Quarter 2012 Financial Results on Wednesday, May 9, 2012
11. Henry Schein to Webcast First Quarter 2012 Conference Call Tuesday, May 8, at 10:00 a.m. EDT
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2016)... , May 4, 2016 ... of the  "Global Acute Ischemic Stroke Market ... to their offering.       (Logo: ... Global Acute Ischemic Stroke Market and Competitive ... Acute Ischemic Stroke pipeline products, Acute Ischemic ...
(Date:5/3/2016)... PUNE, India , May 4, 2016 /PRNewswire/ ... report spreads across 154 pages, profiling 09 key ... It is a professional and in-depth study on ... providing a basic overview of the industry including ... Insulin Needles market analysis is provided for the ...
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
Breaking Medicine Technology:
(Date:5/6/2016)... (PRWEB) , ... May 06, 2016 , ... From the ... Presence Technology will share its insights on managing Customers Engagement at SpeechTek ... At SpeechTek 2016, Presence Technology will deliver a Presentation on “5 Customer ...
(Date:5/6/2016)... Diego, CA (PRWEB) , ... May 06, 2016 , ... ... Companies, has been family-owned and operated for over 35 years. Maintaining core values of ... has driven their success and made them a leading name in San Diego plumbing, ...
(Date:5/6/2016)... , ... May 06, 2016 , ... This Mother’s Day ... women everywhere. The 17th annual National Women’s Health Week takes place May ... Women’s Health are combining forces to empower women to make their health a top ...
(Date:5/5/2016)... ... May 05, 2016 , ... TransWipe Volume 3 is a ... Drag and drop a TransWipe preset between two video clips to instantly add a ... to colored panels with customizable color and orientation options. TransWipe Volume 3 is a ...
(Date:5/5/2016)... Texas (PRWEB) , ... May 05, 2016 , ... ... the Responsible Wool Standard (RWS) for public stakeholder review. The stakeholder review is an ... that it meets its goals and delivers value to the wool industry., The RWS ...
Breaking Medicine News(10 mins):